Compare · AMIX vs MDLN
AMIX vs MDLN
Side-by-side comparison of Autonomix Medical Inc. (AMIX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMIX and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $50.91B, about 32087.8x AMIX ($1.6M).
- Over the past year, AMIX is down 87.8% and MDLN is down 4.8% - MDLN leads by 83.0 points.
- AMIX has been more active in the news (7 items in the past 4 weeks vs 4 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 0 for AMIX).
PerformanceAMIX-73.60%MDLN-4.83%
2025-12-17+0.00%2026-07-24
- Company
- Autonomix Medical Inc.
- Medline Inc.
- Price
- $3.43-9.97%
- $38.78+3.02%
- Market cap
- $1.6M
- $50.91B
- 1M return
- -51.83%
- +7.57%
- 1Y return
- -87.81%
- -4.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2025
- News (4w)
- 7
- 4
- Recent ratings
- 0
- 25
Latest AMIX
- Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
- Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform
- Autonomix Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform
- Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
- Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
- Autonomix Medical Inc. filed SEC Form 8-K: Other Events
- Autonomix Medical Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change
- Autonomix Announces Reverse Stock Split
Latest MDLN
- Medline strengthens California distribution network with new 1 million-square-foot facility in Perris
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)